• Gerry Brunk, Managing Director, Lumira Ventures
Gerry Brunk is a Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Since joining the firm in 2002 to open its Boston office he has invested in and served on the boards of directors of over 25 life science companies, including Pharmasset (acquired by Gilead Sciences), MAKO Surgical (acquired by Stryker), Corvia Medical, Satsuma Pharmaceuticals (Nasdaq: STSA), Cardiac Dimensions, KAI Pharmaceuticals (acquired by Amgen), Endotronix, BardyDx, HistoSonics and Engage Therapeutics. Before joining Lumira Ventures, Gerry was an entrepreneur who co-founded and served in a variety of management and board capacities at start-up companies in the pharmacy benefit management, senior living and technology transfer sectors. He was previously an engagement manager in the healthcare practice of The Boston Consulting Group and a member of the investment banking group of Credit Suisse First Boston where his clients included public and private healthcare companies. Gerry holds an MBA from Stanford Graduate School of Business and a BA from the University of Virginia, where he studied biology and economics.